Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Yamamoto, D. Cooper (2003)
An investigation of the effect of thalidomide on anti‐gal antibody production in baboonsXenotransplantation, 10
Bettina Baumann, G. Stussi, K. Huggel, R. Rieben, J. Seebach (2007)
Reactivity of Human Natural Antibodies to Endothelial Cells From Gal&agr;(1,3)Gal-Deficient PigsTransplantation, 83
E. Woodle, R. Alloway, A. Girnita (2011)
Proteasome inhibitor treatment of antibody-mediated allograft rejectionCurrent Opinion in Organ Transplantation, 16
J. Simmonds, C. Dewar, H. Dawkins, M. Burch, M. Fenton (2009)
Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid‐free, statin eraClinical Transplantation, 23
G. Hutter, M. Rieken, A. Pastore, O. Weigert, Y. Zimmermann, M. Weinkauf, W. Hiddemann, M. Dreyling (2012)
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphomaAnnals of Hematology, 91
M. Everly, P. Terasaki, J. Hopfield, H. Trivedi, H. Kaneku (2010)
Protective Immunity Remains Intact After Antibody Removal by Means of Proteasome InhibitionTransplantation, 90
B. Besse, D. Planchard, A. Veillard, L. Taillade, D. Khayat, M. Ducourtieux, J. Pignon, J. Lumbroso, Carole Lafontaine, C. Mathiot, J. Soria (2012)
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.Lung cancer, 76 1
B. Sadaka, R. Alloway, S. Woodle (2011)
Clinical and investigational use of proteasome inhibitors for transplant rejectionExpert Opinion on Investigational Drugs, 20
V. Kute, A. Vanikar, H. Trivedi, P. Shah, Kamal Goplani, H. Patel, M. Gumber, Rashmi Patel, K. Kanodia, K. Suthar, Varsha Trivedi, P. Modi (2011)
Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 22 4
H. Hara, M. Ezzelarab, P. Rood, Y. Lin, J. Busch, Z. Ibrahim, Xiaocheng Zhu, S. Ball, D. Ayares, A. Zeevi, M. Awwad, D. Cooper (2006)
Allosensitized humans are at no greater risk of humoral rejection of GT‐KO pig organs than other humansXenotransplantation, 13
(2010)
Early graft failure of GTKO pig organs in baboons is reduced by HCPRP expression (Abstract 499)
M. Everly, J. Everly, B. Susskind, P. Brailey, L. Arend, R. Alloway, P. Roy-Chaudhury, A. Govil, G. Mogilishetty, A. Rike, M. Cardi, G. Wadih, A. Tevar, S. Woodle (2008)
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute RejectionTransplantation, 86
N. Cretin, Jennifer Bracy, K. Hanson, J. Iacomini (2002)
The Role of T Cell Help in the Production of Antibodies Specific for Galα1–3Gal1The Journal of Immunology, 168
R. Sberro-Soussan, Julien Zuberl, C. Suberbielle-Boissel, C. Legendre (2010)
Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.Clinical transplants
M. Everly (2009)
A summary of bortezomib use in transplantation across 29 centers.Clinical transplants
E. Scott, D. Reece (2011)
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?Hematology. American Society of Hematology. Education Program, 2011
K. Anderson (2012)
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 4
Peter Yeh, M. Ezzelarab, N. Bovin, H. Hara, Cassandra Long, K. Tomiyama, Frank Sun, D. Ayares, M. Awwad, D. Cooper (2010)
Investigation of potential carbohydrate antigen targets for human and baboon antibodiesXenotransplantation, 17
M. Ezzelarab, B. Garcia, A. Azimzadeh, Hongtao Sun, C. Lin, H. Hara, S. Kelishadi, Tianshu Zhang, Y. Lin, H. Tai, R. Wagner, J. Thacker, N. Murase, K. McCurry, R. Barth, D. Ayares, R. Pierson, D. Cooper (2009)
The Innate Immune Response and Activation of Coagulation in α1,3-Galactosyltransferase Gene-Knockout Xenograft RecipientsTransplantation, 87
U. Galili, R. Mandrell, Randa Hamadeh, S. Shohet, J. Griffiss (1988)
Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human floraInfection and Immunity, 56
H. Trivedi, A. Vanikar, M. Gumber, H. Patel, P. Shah, V. Kute (2012)
Abrogation of antibodies improves outcome of renal transplantation.Transplantation proceedings, 44 1
R. Sberro-Soussan, J. Zuber, J. Zuber, C. Suberbielle-Boissel, S. Candon, S. Candon, F. Martinez, R. Snanoudj, M. Rabant, M. Rabant, N. Pallet, N. Pallet, D. Nochy, D. Anglicheau, D. Anglicheau, M. Leruez, M. Leruez, A. Loupy, A. Loupy, E. Thervet, E. Thervet, O. Hermine, O. Hermine, C. Legendre, C. Legendre (2010)
Bortezomib as the Sole Post‐Renal Transplantation Desensitization Agent Does Not Decrease Donor‐Specific Anti‐HLA AntibodiesAmerican Journal of Transplantation, 10
C. McGregor, D. Ricci, N. Miyagi, P. Stalboerger, Z. Du, E. Oehler, H. Tazelaar, G. Byrne (2012)
Human CD55 Expression Blocks Hyperacute Rejection and Restricts Complement Activation in Gal Knockout Cardiac XenograftsTransplantation, 93
Leo Buhler, D. Pidwell, R. Dowling, D. Newman, M. Awwad, D. Cooper (1999)
Different responses of human anti‐HLA and anti‐αgal antibody to long‐term intravenous immunoglobulin therapyXenotransplantation, 6
D. Aguila, L. Tantalo, N. Liebermann, Q. Phung (2021)
NONHUMAN PRIMATES
Shimizu (2008)
Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from α1,3-galactosyltransferase gene-knockout pigs in baboonsAm J Pathol, 172
A. Shimizu, Y. Hisashi, K. Kuwaki, Y. Tseng, F. Dor, S. Houser, S. Robson, H. Schuurman, D. Cooper, D. Sachs, Kazuhiko Yamada, R. Colvin (2010)
Cardiovascular , Pulmonary and Renal Pathology Thrombotic Microangiopathy Associated with Humoral Rejection of Cardiac Xenografts from 1 , 3-Galactosyltransferase Gene-Knockout Pigs in Baboons
Martina Guthoff, B. Schmid-Horch, K. Weisel, H. Häring, A. Königsrainer, N. Heyne (2012)
Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.Transplant immunology, 26 4
H. Ohdan, Y. Yang, K. Swenson, A. Thall, M. Sykes (2000)
In vivo T-cell depletion enhances production of anti-GALalpha1,3GAL natural antibodies in alpha1,3-galactosyltransferase-deficient mice.Transplantation, 69 5
M. Everly, P. Terasaki (2012)
The state of therapy for removal of alloantibody producing plasma cells in transplantation.Seminars in immunology, 24 2
Azimzadeh (2010)
Early graft failure of GTKO pig organs in baboons is reduced by HCPRP expressionAm J Transplant, 10
B. Gollackner, S. Goh, I. Qawi, L. Buhler, C. Knosalla, S. Daniel, E. Kaczmarek, M. Awwad, D. Cooper, S. Robson (2004)
ACUTE VASCULAR REJECTION OF XENOGRAFTS: ROLES OF NATURAL AND ELICITED XENOREACTIVE ANTIBODIES IN ACTIVATION OF VASCULAR ENDOTHELIAL CELLS AND INDUCTION OF PROCOAGULANT ACTIVITYTransplantation, 77
P. Cowan (2007)
Coagulation and the xenograft endotheliumXenotransplantation, 14
M. Ezzelarab, H. Hara, J. Busch, P. Rood, Xiaocheng Zhu, Z. Ibrahim, S. Ball, D. Ayares, M. Awwad, D. Cooper (2006)
Antibodies directed to pig non‐Gal antigens in naïve and sensitized baboonsXenotransplantation, 13
N. Cretin, Jennifer Bracy, K. Hanson, J. Iacomini (2002)
The role of T cell help in the production of antibodies specific for Gal alpha 1-3Gal.Journal of immunology, 168 3
T. Diwan, S. Raghavaiah, J. Burns, W. Kremers, J. Gloor, M. Stegall (2011)
The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In VivoTransplantation, 91
L. Bühler, M. Basker, I. Alwayn, C. Goepfert, H. Kitamura, T. Kawai, S. Gojo, T. Kozłowski, F. Ierino, M. Awwad, D. Sachs, R. Sackstein, S. Robson, D. Cooper (2000)
COAGULATION AND THROMBOTIC DISORDERS ASSOCIATED WITH PIG ORGAN AND HEMATOPOIETIC CELL TRANSPLANTATION IN NONHUMAN PRIMATESTransplantation, 70
M. Wahrmann, M. Haidinger, G. Körmöczi, T. Weichhart, M. Säemann, R. Geyeregger, Ž. Kikić, Thomas Prikoszovich, J. Drach, G. Böhmig (2010)
Effect of the Proteasome Inhibitor Bortezomib on Humoral Immunity in Two Presensitized Renal Transplant CandidatesTransplantation, 89
J. Waiser, K. Budde, M. Schütz, L. Liefeldt, B. Rudolph, C. Schönemann, H. Neumayer, N. Lachmann (2012)
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 27 3
Maha Mohamed, D. Lorentzen, Jim Kim, A. Djamali (2011)
Desensitization across the HLA barrier in kidney transplantaion.Frontiers in bioscience, 3
D. Harper, B. Gollackner, Y. Xu, D. Calderhead, D. Ryan, W. Li, J. Chang, C. Wu, K. Moran, D. Latinne, H. Bazin, M. White-Scharf, D. Cooper, M. Awwad (2004)
In vitro and in vivo investigation of a novel monoclonal antibody to plasma cells (W5 mAb)Xenotransplantation, 11
D. Lambrigts, P. Calster, Yuanxin Xu, M. Awwad, F. Neethling, T. Kozłowski, A. Foley, A. Watts, Sanders Chae, J. Fishman, A. Thall, M. White-Scharf, D. Sachs, D. Cooper (1998)
Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti‐αGal antibody in the baboonXenotransplantation, 5
Tomasz Kozlowski, A. Shimizu, D. Lambrigts, Kazuhiko Yamada, Yasushi Fuchimoto, Roseann Glaser, Rod Monroy, Yuanxin Xu, M. Awwad, Robert Colvin, A. Cosimi, Simon Robson, Jay Fishman, Thomas Spitzer, D. Cooper, David Sachs (1999)
Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption.Transplantation, 67 1
S. Flechner, R. Fatica, M. Askar, B. Stephany, E. Poggio, A. Koo, Stacey Banning, Andres Chiesa-Vottero, T. Srinivas (2010)
The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ TransplantationTransplantation, 90
R. Walsh, R. Alloway, A. Girnita, E. Woodle (2012)
Proteasome inhibitor-based therapy for antibody-mediated rejection.Kidney international, 81 11
E. Woodle, R. Walsh, R. Alloway, A. Girnita, P. Brailey (2011)
Proteasome inhibitor therapy for antibody‐mediated rejectionPediatric Transplantation, 15
J. Everly, R. Walsh, R. Alloway, E. Woodle (2009)
Proteasome inhibition for antibody-mediated rejectionCurrent Opinion in Organ Transplantation, 14
P. Cowan, J. Roussel, A. D'apice (2009)
The vascular and coagulation issues in xenotransplantationCurrent Opinion in Organ Transplantation, 14
M. Wahrmann, M. Haidinger, J. Drach, R. Geyeregger, Ž. Kikić, R. Raab, M. Säemann, G. Böhmig (2009)
Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.Clinical transplants
Dana Perry, Justin Burns, H. Pollinger, B. Amiot, J. Gloor, G. Gores, M. Stegall (2008)
Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody ProductionAmerican Journal of Transplantation, 9
B. Gollackner, D. Ryan, C. Knosalla, M. Basker, I. Alwayn, D. Harper, G. Salomon, S. Mauiyyedi, L. Correa, A. Thall, D. Cooper (2003)
An exploratory investigation of the effect of arsenic trioxide on anti‐Gal antibody production in baboonsXenotransplantation, 10
M. Kujundžić, E. Koren, F. Neethling, Franko Mitotic, M. Koscec, Tatjana Kujundzic, Mic Martin, D. Cooper (1994)
Variability of anti‐αGal antibodies in human serum and their relation to serum cytotoxicity against pig cellsXenotransplantation, 1
R. Shapiro, J. Lunz, A. Zeevi, A. Basu, M. Mapara, P. Randhawa, H. Tan, V. Sharma, A. Humar (2010)
1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.Clinical transplants
B. Lonze, N. Dagher, C. Simpkins, A. Singer, D. Segev, A. Zachary, R. Montgomery (2009)
The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.Clinical transplants
T. Mujtaba, Q. Dou (2011)
Advances in the understanding of mechanisms and therapeutic use of bortezomib.Discovery medicine, 12 67
A. Rike, G. Mogilishetty, R. Alloway, P. Succop, P. Roy-Chaudhury, M. Cardi, T. Kaiser, Mark Thomas, E. Woodle (2007)
Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroidsClinical Transplantation, 22
K. Kuwaki, Y. Tseng, F. Dor, A. Shimizu, S. Houser, T. Sanderson, C. Lancos, D. Prabharasuth, Jane Cheng, K. Moran, Y. Hisashi, N. Mueller, Kazuhiko Yamada, J. Greenstein, R. Hawley, C. Patience, M. Awwad, J. Fishman, S. Robson, H. Schuurman, D. Sachs, D. Cooper (2005)
Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experienceNature Medicine, 11
I. Alwayn, Yuanxin Xu, M. Basker, Cecelia Wu, L. Buhler, D. Lambrigts, S. Treter, D. Harper, H. Kitamura, E. Vitetta, Sonny Abraham, M. Awwad, M. White-Scharf, D. Sachs, A. Thall, D. Cooper (2001)
Effects of specific anti‐B and/or anti‐plasma cell immunotherapy on antibody production in baboons: depletion of CD20‐ and CD22‐positive B cells does not result in significantly decreased production of anti‐αGal antibodyXenotransplantation, 8
R. Walsh, J. Everly, P. Brailey, A. Rike, L. Arend, G. Mogilishetty, A. Govil, P. Roy-Chaudhury, R. Alloway, E. Woodle (2010)
Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft RejectionTransplantation, 89
A. Idica, H. Kaneku, M. Everly, H. Trivedi, A. Feroz, A. Vanikar, V. Shankar, Varsha Trivedi, P. Modi, S. Khemchandani, S. Dave, P. Terasaki (2008)
Elimination of post-transplant donor-specific HLA antibodies with bortezomib.Clinical transplants
E. Dons, Claudia Montoya, Cassandra Long, H. Hara, G. Echeverri, B. Ekser, Corin Ezzelarab, Dasha Medellín, D. Windt, N. Murase, L. Rigatti, R. Wagner, R. Wolf, M. Ezzelarab, L. West, J. Ijzermans, D. Cooper (2012)
T-Cell-Based Immunosuppressive Therapy Inhibits the Development of Natural Antibodies in Infant BaboonsTransplantation, 93
W. Morrow, E. Frazier, W. Mahle, T. Harville, S. Pye, K. Knecht, Emily Howard, R. Smith, R. Saylors, X. Garcia, R. Jaquiss, S. Woodle (2012)
Rapid Reduction in Donor-Specific Anti-Human Leukocyte Antigen Antibodies and Reversal of Antibody-Mediated Rejection With Bortezomib in Pediatric Heart Transplant PatientsTransplantation, 93
E. Island, I. Gonzalez-Pinto, H. Tsai, P. Ruiz, P. Tryphonopoulos, Mónica González, J. Solano, Marie Rossique, G. Selvaggi, A. Tekin, Lesley Smith, A. Tzakis (2009)
Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.Clinical transplants
A. Azimzadeh, S. Kelishadi, T. Stoddard, Tao Zhang, M. Ezzelarab, E. Welty, C. Avon, B. Nguyen, A. Laaris, Xiangfei Cheng, D. Ayares, D. Cooper, R. Barth, R. Pierson (2010)
Role of complement regulatory protein expression and CD154 blockade in Gal-independent xenograft rejectionXenotransplantation, 17
N. Schmidt, R. Alloway, R. Walsh, B. Sadaka, A. Shields, A. Girnita, D. Hanseman, E. Woodle (2012)
Prospective Evaluation of the Toxicity Profile of Proteasome Inhibitor–Based Therapy in Renal Transplant Candidates and RecipientsTransplantation Journal, 94
Pleunic Rood, H. Hara, J. Busch, M. Ezzelarab, Xiaocheng Zhu, S. Ball, D. Ayares, M. Awwad, D. Cooper (2006)
Incidence and cytotoxicity of antibodies in cynomolgus monkeys directed to nonGal antigens, and their relevance for experimental modelsTransplant International, 19
R. Boothpur, Stephanie Torrence, D. Brennan (2009)
Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization.Clinical transplants
F. Paterno, M. Shiller, G. Tillery, J. O’Leary, B. Susskind, J. Trotter, G. Klintmalm (2012)
Bortezomib for Acute Antibody‐Mediated Rejection in Liver TransplantationAmerican Journal of Transplantation, 12
K. Neben, H. Lokhorst, A. Jauch, U. Bertsch, T. Hielscher, B. Holt, H. Salwender, I. Blau, K. Weisel, M. Pfreundschuh, C. Scheid, U. Dührsen, W. Lindemann, I. Schmidt-Wolf, N. Peter, C. Teschendorf, H. Martin, M. Haenel, H. Derigs, M. Raab, A. Ho, H. Velde, D. Hose, P. Sonneveld, H. Goldschmidt (2012)
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.Blood, 119 4
H. Trivedi, P. Terasaki, A. Feroz, M. Everly, A. Vanikar, V. Shankar, Varsha Trivedi, H. Kaneku, A. Idica, P. Modi, S. Khemchandani, S. Dave (2009)
Abrogation of Anti-HLA Antibodies via Proteasome InhibitionTransplantation, 87
S. Houser, K. Kuwaki, C. Knosalla, F. Dor, B. Gollackner, Jane Cheng, A. Shimizu, H. Schuurman, D. Cooper (2004)
Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboonsXenotransplantation, 11
K. Teranishi, S. Treter, I. Alwayn, L. Buhler, M. Awwad, D. Cooper (2001)
Assessment of methotrexate as a potential immunosuppressive agent in baboons.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 20 12
H. Trivedi, P. Terasaki, A. Feroz, A. Vanikar, Varsha Trivedi, S. Khemchandani, S. Dave, V. Shankar, P. Modi, H. Kaneku, A. Idica, M. Everly (2010)
Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.Transplantation, 90 2
Background Bortezomib, a proteasome inhibitor used to treat multiple myeloma, has been administered (± plasma exchange ± intravenous immunoglobulin (IVIg)) in attempts to reduce antibodies against human leukocyte antigens (HLA) in sensitized patients undergoing organ transplantation. To our knowledge, bortezomib has not been investigated for its effect on natural anti‐pig antibodies. If bortezomib could reduce the production of anti‐pig antibodies, this would likely be beneficial to the outcome of pig organ grafts in primates. Methods Nine patients received bortezomib either to reduce anti‐HLA antibody levels before organ allotransplantation or to treat antibody‐mediated rejection. Patients at the Mayo Clinic (Group 1; n = 4) received bortezomib alone, whereas at the UPMC (Group 2; n = 5), this was combined with plasmaphereses ± IVIg in some cases. Anti‐pig IgM and IgG levels against wild‐type (WT) and α1,3‐galactosyltransferase gene knockout (GTKO) pig aortic endothelial cells (flow cytometry—relative mean fluorescence intensity) and anti‐Gal IgM and IgG (ELISA–OD480 nm) were measured pre‐ and post‐bortezomib therapy. Results Mean anti‐pig IgM levels were 11.2 (WT) and 1.9 (GTKO) pre‐bortezomib treatment and 9.4 (WT: P = 0.02) and 1.7 (GTKO: P = 0.33) post‐bortezomib treatment, respectively. Mean anti‐pig IgG levels were 4.3 (WT) and 1.5 (GTKO) pre‐bortezomib treatment and 3.6 (WT: P = 0.21) and 1.4 (GTKO: P = 0.20) post‐bortezomib treatment, respectively. Mean anti‐Gal IgM and IgG levels were 0.7 and 1.1, respectively, pre‐treatment, and 0.6 (P = 0.03) and 1.1 (NS), respectively, post‐treatment. When the data were analyzed in Groups 1 and 2 separately, there were no significant differences between the pre‐ and post‐bortezomib levels of anti‐pig, anti‐non‐Gal, or anti‐Gal IgM or IgG. Conclusions From this limited study, we conclude that bortezomib might reduce anti‐Gal IgM levels in primates, but, in this respect alone, is unlikely to have any significant effect on the outcome of GTKO pig organ transplantation.
Xenotransplantation – Wiley
Published: Nov 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.